GRI
GRI Bio Inc.
NASDAQ: GRI · HEALTHCARE · BIOTECHNOLOGY
$2.23
-5.51% today
Updated 2026-04-29
Market cap
$3.41M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-121.80
Dividend yield
—
52W range
$2 – $80
Volume
0.1M
GRI Bio Inc. (GRI) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $100000.00 | $0.00 | $0.00 | $21.77M | $22.54M | $0.00 |
| Revenue growth (YoY) | — | — | — | -100.0% | — | — | +3.5% | -100.0% |
| Cost of revenue | $612.00 | $735.00 | $100000.00 | $73000.00 | $50000.00 | $57000.00 | $4000.00 | $4000.00 |
| Gross profit | $-612.00 | $-735.00 | $100000.00 | $-73000.00 | $-50000.00 | $-57000.00 | $-4000.00 | $-4000.00 |
| Gross margin | — | — | 100.0% | — | — | -0.3% | -0.0% | — |
| R&D | $3.51M | $1.88M | $264000.00 | $5.19M | $242000.00 | $3.23M | $3.77M | $6.82M |
| SG&A | — | — | $1.20M | $813000.00 | $2.00M | $8.10M | $4.41M | $5.16M |
| Operating income | $-4.31M | $-3.15M | $-1.46M | $-9.26M | $-2.24M | $-11.39M | $-8.23M | $-11.98M |
| Operating margin | — | — | -1459.0% | — | — | -52.3% | -36.5% | — |
| EBITDA | $-4.31M | $-3.27M | $-1.46M | $-9.21M | $-2.51M | $-10.90M | $-8.20M | $-11.97M |
| EBITDA margin | — | — | -1456.0% | — | — | -50.1% | -36.4% | — |
| EBIT | $-4.31M | $-3.27M | $-1.46M | $-9.29M | $-2.56M | $-10.96M | $-8.21M | $-11.98M |
| Interest expense | — | $197026.00 | $34000.00 | $16000.00 | $653000.00 | $2.08M | $6000.00 | — |
| Income tax | $-2.00 | $5.00 | $-131297.00 | $-50000.00 | $325000.00 | $2.77M | — | — |
| Effective tax rate | 0.0% | -0.0% | 4.9% | 0.5% | -11.2% | -26.9% | 0.0% | 0.0% |
| Net income | $-4.31M | $-3.46M | $-2.53M | $-9.30M | $-3.22M | $-13.04M | $-8.21M | $-11.96M |
| Net income growth (YoY) | — | +19.7% | +26.9% | -267.6% | +65.4% | -305.3% | +37.0% | -45.7% |
| Profit margin | — | — | -2531.0% | — | — | -59.9% | -36.4% | — |